Adverse Event Reporting: The FDA has highlighted concerns about adverse events associated with compounded GLP-1 medications, sometimes related to dosing errors or measurement issues
For people actively losing weight on semaglutide, a couple of these functions are especially relevant
Mutation rate varies among cancer subtypes, with some, such as high-grade serous ovarian cancer (HGSOC), reaching upwards of 96% [3]
Currently, two ongoing clinical trials are investigating the role of GLP-1 RAs in IBD management, that would lead to further knowledge: a French study (ID NCT05196958) evaluating the safety and efficacy of GLP-1 RAs in treatment of DM2 in overweight IBD patients (115), and an American study (ID NCT06774079) comparing the efficacy of GLP-1 RAs tirzepatide versus diet in CD patients (116)
Labs ordered as needed before or during treatment based on your medical history
Concurrent use with other sympathomimetics (OTC cold medications) may produce hypertension
